Skip to main content
Pasithea Therapeutics Corp. logo

Pasithea Therapeutics Corp. — Investor Relations & Filings

Ticker · KTTA ISIN · US70261F1030 US Professional, scientific and technical activities
Filings indexed 301 across all filing types
Latest filing 2025-12-01 Director's Dealing
Country US United States of America
Listing US KTTA

About Pasithea Therapeutics Corp.

https://www.pasithea.com/

Pasithea Therapeutics Corp. is a clinical-stage biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders and RASopathies. The company develops new therapeutics for neurological and psychiatric conditions, with a primary focus on Neurofibromatosis type 1 (NF1), a disorder causing tumor growth along nerves, and Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative disease. Its research also targets Multiple Sclerosis (MS), a chronic autoimmune disease of the CNS, and schizophrenia, a disabling psychiatric illness. The company's pipeline additionally includes treatments for solid tumors.

Recent filings

Filing Released Lang Actions
Director's Dealing 2025
Director's Dealing
2025-12-01 English
Director's Dealing 2025
Director's Dealing
2025-12-01 English
Director's Dealing 2025
Director's Dealing
2025-12-01 English
Director's Dealing 2025
Director's Dealing
2025-12-01 English
Director's Dealing 2025
Director's Dealing
2025-12-01 English
PROSPECTUS
Regulatory Filings
2025-12-01 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.